PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diagnosis of primary central nervous system (CNS) malignancy at time of diagnosis or recurrence
• * Histology verification not required for intrinsic brain stem tumors and optic pathway gliomas
• * Must have radiographic evidence of progression
• Recurrent, progressive, or refractory disease to standard therapy and for which there is no known curative therapy
• PATIENT CHARACTERISTICS:
• Karnofsky performance status (PS) 50-100% (patients \> 16 years of age) OR Lansky PS 50-100% (patients ≤ 16 years of age)
• Body weight ≥ 15 kg and ≤ 100 kg
• Patients with neurological deficits allowed provided they are stable for ≥ 1 week
• Able to swallow capsules
• ANC ≥ 1,000/μL (unsupported)
• Platelet count ≥ 100,000/μL (unsupported)
• Hemoglobin ≥ 8 g/dL (may be supported)
• Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m\^2 OR serum creatinine normal based on age as follows:
• * 0.8 mg/dL (≤ 5 years of age)
• * 1.0 mg/dL (\> 5 to ≤ 10 years of age)
• * 1.2 mg/dL (\> 10 to ≤ 15 years of age)
• * 1.5 mg/dL (\> 15 years of age)
• Urine protein/creatinine ratio \< 1.0
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN
• Albumin ≥ 2.5 g/dL
• PT and activated PTT ≤ 1.2 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No clinically significant unrelated systemic illness that would compromise the patient's ability to tolerate protocol therapy, or would likely interfere with the study procedures or results, including any of the following:
• * Serious infections including ongoing systemic bacterial, fungal, or viral infection
• * Significant cardiac, pulmonary, hepatic, or other organ dysfunction
• Willing and able to comply with schedule visits, drug administration plan, laboratory tests, including pharmacokinetic and pharmacodynamic assessments, or other study procedures
• No known coagulopathy or bleeding diathesis
• No known history of drug-induced liver injury
• No CNS, pulmonary, gastrointestinal, or urinary bleeding within the past month
• No uncontrolled systemic hypertension (systolic BP or diastolic BP \> 95% percentile for age)
• No alcohol or drug addiction
• Able to tolerate periodic MRI scans and gadolinium contrast
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from the acute toxic of all prior therapy (excluding alopecia and neurotoxicity)
• At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosourea)
• At least 14 days since prior investigational or biological agent
• * At least 3 half-lives since prior biological agents that have a prolonged half-life
• At least 3 half-lives since prior monoclonal antibody
• At least 2 weeks since prior local palliative radiotherapy
• At least 6 weeks since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis
• At least 90 days since prior allogeneic bone marrow transplantation
• * No active graft-versus-host disease
• Concurrent dexamethasone or other corticosteroids allowed provided dose is stable for ≥ 7 days
• At least 1 week since prior colony-forming growth factors (e.g., filgrastim, sargramostim, erythropoietin)
• * At least 14 days since long-acting colony-forming growth factor formulations (e.g., pegfilgrastim)
• More than 4 weeks since prior major surgical procedures
• * More than 2 weeks since prior intermediate surgical procedures
• * More than 7 days since minor surgical procedures
• No other concurrent anticancer or investigational drug therapy